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Summary
The diagnosis of invasive pulmonary aspergillosis (IPA) increasingly relies on non- 
culture- based biomarkers in bronchoalveolar lavage (BAL) fluid. The Aspergillus lateral 
flow device (LFD) is a rapid immunoassay that uses a novel Aspergillus monoclonal 
antibody to gain specificity. The objective of the study is to compare specificity and 
sensitivity of the prototype LFD and the galactomannan (GM) enzyme immunoassay in 
BAL fluid in high- risk patients. A total of 114 BAL samples from 106 patients at high 
risk for IPA were studied: 8 patients had proven/probable IPA, 16 had possible IPA 
and 82 did not have IPA. In patients with proven/probable IPA, specificity of LFD was 
94% and GM was 89%; sensitivity of LFD was 38% and GM was 75%. Negative predic-
tive value (NPV) for LFD was 94% and for GM was 98%; positive predictive value 
(PPV) was 38% for both tests. The use of anti- mould prophylaxis did not affect speci-
ficity but resulted in decreased NPV of both LFD and GM. Union and intersection 
analysis showed no improvement in the performance by using both tests. Among pa-
tients at risk for IPA, the diagnostic performance of LFD and GM in BAL fluid appears 
comparable; specificity is high, but sensitivity of both LFD and GM is poor.
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1  | INTRODUCTION
Invasive pulmonary aspergillosis (IPA) remains a deadly disease, with 
mortality rates as high as 35%- 57% reported among haematopoietic 
cell transplant (HCT) recipients, patients with acute leukaemia and 
liver transplant recipients.1-3 Prompt initiation of antifungal therapy 
improves survival, but early diagnosis remains challenging.4,5 To estab-
lish a diagnosis of proven IPA, clinicians are tasked with obtaining a 
sterile specimen or tissue for histopathology from which Aspergillus 
must be isolated or seen invading tissue.6 However, invasive proce-
dures are often contraindicated in patients at greatest risk for this 
infection, and clinicians are often faced with the dilemma of starting 
empirical antifungal therapy.
Non- invasive diagnostic biomarkers, such as Aspergillus galac-
tomannan (GM) and 1,3 beta- D- glucan (BDG), are included in the 
EORTC/MSG criteria for the diagnosis of probable IPA. The role of 
serum and bronchoalveolar lavage (BAL) GM in diagnosis has been 
best established for patients who have haematological malignancies.7 
However, the use of serum and BAL GM in other populations, such as 
solid organ transplant recipients, remains undefined,8,9 and the serum 
BDG assay is not specific for Aspergillus.
The Aspergillus immunochromatographic assay (Isca Diagnostics, 
Truro, Cornwall, UK) is a prototype lateral flow device (LFD) that uses 
an Aspergillus- specific monoclonal antibody (mAb JF5) for the diag-
nosis of IPA.10 This assay enables point- of- care testing for the rapid 
diagnosis of IPA using technology similar to that used to diagnose 
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pregnancy.11 Initial studies on the performance of LFD in BAL fluid 
demonstrated sensitivity and specificity as high as 100% and 95%, re-
spectively,12-14 but further clinical experience is needed to define the 
role of this assay for the diagnosis of IPA.
We sought to determine the utility of the Aspergillus LFD for the 
diagnosis of IPA in BAL samples from at- risk patients. We compared 
the performance characteristics of the Aspergillus LFD to that of GM 
in BAL fluid in these patients.
2  | METHODS
2.1 | Patients
This study was performed at the University of Michigan Health 
System, a 1000- bed tertiary care medical centre in southeastern 
Michigan. Approval was obtained from the University of Michigan 
Medical Center Institutional Review Board.
From September 1, 2014 through August 30, 2015, patients 
who were identified as being at risk for IPA and who had under-
gone bronchoscopy with BAL were included in the study. Patients 
considered at risk were those who had classic risk factors as de-
fined by EORTC/MSG guidelines: neutropenia (≤500 neutrophils/
μL) for more than 10 days, allogeneic HCT, solid organ transplant, 
inherited severe immunodeficiency, prolonged use of corticoste-
roids (≥0.3 mg/kg/day prednisone equivalent ≥3 weeks) or treat-
ment with T- cell immunosuppressive agents, such as cyclosporine, 
tumour necrosis factor antagonists, specific monoclonal antibodies 
or nucleoside analogues, during the previous 3 months.6 Other at- 
risk patients included in the study were those who had a prolonged 
intensive care unit stay (>21 days), severe burns or near- drowning, 
autoimmune disease treated with immunosuppressive agents, HIV 
with CD4 count <200/μL, chronic pulmonary disease or solid tu-
mour treated with chemotherapy in the preceding 30 days.
Exclusion criteria included age <18 years, inadequate BAL spec-
imen (either due to quantity or quality of specimen) to perform GM 
and LFD testing and patients who had a BAL performed for a pur-
pose other than evaluation for possible IPA. If patients had several 
BALs within a 14- day period, only the first specimen was included in 
this study. BAL samples from the same patient that were collected 
>2 weeks from the first BAL sample were tested and recorded as a 
separate episode.
Proven, probable and possible IPA were defined according to 
EORTC/MSG criteria.6 Additionally, the algorithm proposed by Blot 
et al15 was used to define IPA in non- neutropenic patients. For this 
study, biomarker detection in serum or BAL samples was not used as 
part of the diagnostic criteria for probable IPA. Information regarding 
host risk factors and diagnostic criteria for IPA was abstracted by chart 
review.
2.2 | Specimens and assays
BAL samples were prospectively collected using normal saline from 
consecutive bronchoscopies performed during the study period. BAL 
samples were stored at 4°C for a maximum of 24 h, and aliquots were 
prepared and frozen at −20°C. BAL samples from patients determined 
to be at risk for IPA, as defined above, were stored for LFD testing and 
GM testing, if not previously performed. BAL samples were not pre-
treated before freezing. Specimens remained frozen for a maximum of 
7 months before testing.
Results of serum and BAL Aspergillus GM assays (Platelia™ 
Aspergillus EIA, Viracor- IBT Laboratories, Lee’s Summit, MO, USA) 
obtained for clinical care were recorded. For patients who did not 
have GM testing performed previously on BAL fluid, frozen aliquots 
were sent for testing (Platelia™ Aspergillus EIA, Mira Vista Diagnostics, 
Indianapolis, IN, USA). Results with optical density index (ODI) values 
of >0.5 and ≥1.0 were analysed separately.
The Aspergillus LFD was performed on stored BAL fluid follow-
ing methods described previously.16 Prototype LFD devices were 
purchased from OLM Diagnostics, Newcastle upon Tyne, UK in April 
2015. Testing was performed in two batches: the first in May 2015 
and the second in September 2015. Results were interpreted inde-
pendently by two investigators, both of whom were blinded to the 
source of the BAL. A positive result was indicated by the appearance 
of both a test band and a control band, and a negative result showed 
only the single control band. A positive test was reported as + (weak 
positive), ++ (positive) and +++ (strongly positive) as recommended by 
the manufacturer. If no control band was observed, the test results 
were considered invalid, and the test was repeated if ample specimen 
was available. If inadequate BAL fluid was available for retesting, the 
BAL sample was excluded from analysis.
2.3 | Statistical methods
Sensitivity, specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV) for GM and LFD were calculated using 
r package caret. The differences in sensitivity and specificity be-
tween GM and LFD in the same patient group were tested using 
McNemar’s test with function sesp.mcnemar in r package dtcompair. 
The differences in NPV and PPV between GM and LFD in the same 
patient group were tested using a weighted generalised score test 
with function pv.wgs in r package dtcompair.17 The differences in 
sensitivity, specificity, PPV and NPV for GM and LFD among differ-
ent patient groups were tested using Fisher’s exact test. In addition, 
we performed union and intersection analysis to determine whether 
the combination of both tests (LFD and GM) would impact perfor-
mance in the diagnosis of IPA. For the union of two tests, the test 
result is negative if and only if both tests give negative results. For 
the intersection of two tests, the result is positive if and only if both 
tests give positive results.
3  | RESULTS
3.1 | Patients and diagnoses
We prospectively collected a total of 1211 BAL samples. Of these, 
1056 BAL samples from patients with low risk for IPA or age <18 
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were excluded from the study. Forty- one additional specimens were 
excluded because of inadequate volume or missing clinical data.
A total of 114 BAL samples from 106 unique patients at risk for IPA 
were studied. Ninety- nine patients had one BAL sample, six patients 
had two BAL samples and one patient had three BAL samples included 
in the study. The mean age of the 106 patients was 55.3±16.8 years 
(range 18- 86 years), and 65% were men. Clinical and demographic fea-
tures of 106 patients included in the study are presented in Table 1.
For the 114 BAL samples, the final diagnoses were proven IPA in 
1, probable IPA in 7 samples from 7 patients and possible IPA in 18 
samples from 16 patients by EORTC/MSG criteria. All seven cases 
of probable IPA met criteria for putative IPA according to the criteria 
proposed by Blot et al. None of 16 patients with possible IPA by the 
EORTC/MSG definition met diagnostic criteria for putative IPA by the 
Blot criteria.
An alternative diagnosis was established for the remaining 88 
samples from 82 patients, including 4 for whom other invasive fungal 
infections (fusariosis in 2, mucormycosis in 1 and blastomycosis in 1) 
were present.
3.2 | Performance of LFD and GM in BAL fluid
Among the eight BAL samples from patients with proven/probable 
IPA, the LFD assay was positive in only three. A positive GM assay 
with an ODI cut- off ≥0.5 (GM0.5) was found in six BAL samples. 
Only three out of eight BAL samples tested positive by both LFD and 
GM0.5 assays (Table 2). Eighteen BAL samples were from patients 
with possible IPA. The LFD assay was positive in two of these samples, 
and the GM0.5 was positive in a third sample.
Among the 88 BAL samples from patients who did not have IPA, 
there were 83 negative and 5 positive LFD results. GM0.5 was nega-
tive in 78 and positive in 10 samples. There were more true negative 
test results with LFD when compared with GM0.5.
For proven/probable IPA, the specificity of LFD and GM0.5 was 
94% and 89% respectively (Table 3). The sensitivity of GM0.5 was 
higher (75%) than that of LFD (38%). The NPV for LFD and GM0.5 
tests was 94% and 98% respectively. The PPV was 38% for both LFD 
and GM0.5 (Table 3).
When cases of proven/probable and possible IPA were included, 
the specificity of LFD and GM0.5 was 94% and 89% respectively 
(Table 3). The sensitivity of GM0.5 was slightly higher (27%) than that 
of LFD (19%). The NPV for both LFD and GM0.5 tests was 80%. The 
PPV was low for both LFD (50%) and GM0.5 (41%).
Analysis of the performance of GM0.5 and LFD in the different 
subgroups of patients at risk for IPA overall showed high specificity 
and low sensitivity in all groups (Table 4).
3.3 | Performance of GM using an ODI cut- off of ≥1.0
When the GM cut- off was increased to an ODI of ≥1.0 (GM1.0), the 
number of positive tests was 13, compared with 17 when the cut- 
off was ≥0.5; there were 7 false positive tests with GM1.0 compared 
with 10 false positive tests with GM0.5. Using the GM1.0 cut- off, 
increased specificity only slightly from 89% to 92%, and the sensitiv-
ity decreased from 75% to 62% when proven/probable cases were 
considered (Table 3). Increasing the GM cut- off point to 1.0 did not 
improve performance of the assay in specific patient groups (data not 
shown).
3.4 | Combination LFD and GM testing
We performed union and intersection analyses to determine whether 
the combination of LFD and GM0.5 would impact performance for 
the diagnosis of IPA (Table 3). Obtaining a positive result with either 
the GM0.5 or LFD assay (union analysis), retained the sensitivity of 
the individual test with the highest sensitivity, in this case GM0.5, and 
was more sensitive than using the LFD test alone. Union analysis re-
sulted in a decrease in specificity (86%) compared with the specificity 
of either test alone (94% and 89% for LFD and GM0.5 respectively). 
Intersection analysis in which both assays had to yield a positive re-
sult predictably increased the specificity but only slightly because the 
specificity of the individual assays was high to begin with. The sensi-
tivity was only 38%. Thus, little was gained by performing both assays.
TABLE  1 Clinical and demographic features of 106 patients 
included in the study
Feature
Number of 
patients (%)
Age, mean±SD (years) 55.3 ± 16.8
Men 69 (65.1)
Classic risk factorsa 71 (67)
Neutropenia 10
Allogeneic haematopoietic cell transplant (HCT) 15
Corticosteroids 25
T- cell immunosuppression 42
Chronic granulomatous disease 1
Populations at risk based on underlying condition
Haematological cancer/transplant 30 (29)
Non- HCT 12
HCT/cord transplant 18
Solid organ transplant 24 (22)
Lung transplant 15
Non- lung transplant 9
Non- haematological/non- solid organ transplant 52 (49)
Solid tumour on active chemotherapy 4
Chronic pulmonary diseaseb 18
Critically ill (burn, trauma, ICU) 9
Autoimmune on immunosuppressive drugs 16
Otherc 5
aSeveral patients had more than one classic risk factor.
bEight patients were on high- dose corticosteroids and 10 were on low- 
dose corticosteroids with or without inhaled corticosteroids.
cOther conditions included diabetes mellitus (1), chronic heart disease sec-
ondary to congenital heart disease (1), HIV infection with CD4 <200/μL (1), 
asthma and relapsed solid organ tumour (not on active chemotherapy) (1) 
and sickle cell anaemia (1).
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3.5 | Effect of mould- active prophylaxis on test 
performance
A total of 27 BAL samples were obtained from 24 patients who 
were receiving anti- Aspergillus prophylaxis with voriconazole, posa-
conazole, itraconazole, micafungin or aerosolised or intravenous 
amphotericin B. Two of eight samples were from patients who 
had proven/probable IPA and who were receiving prophylaxis. 
GM0.5 was positive in both samples, and LFD was positive in 
one. Ten samples from nine patients with possible IPA were 
obtained while they were receiving prophylaxis. The GM0.5 
and LFD test were positive in only one patient each. Among 15 
samples from 13 patients who did not have IPA and who were on 
prophylaxis, GM0.5 was positive in 2 and LFD was negative in all 
of them.
The specificity of LFD and GM0.5 was not influenced by anti- 
mould prophylaxis. The specificity of GM0.5 was 87% and 89% among 
patients with and without prophylaxis, respectively, and the specificity 
of LFD was 100% and 93% among patients with and without prophy-
laxis respectively. The NPV was decreased by the use of anti- mould 
prophylaxis from 86% to 60% with the LFD assay and from 87% to 
59% using the GM0.5 assay.
3.6 | Cross- reactivity of LFD and GM assays
Cultures of BAL samples yielded fungal organisms in 38 samples from 
patients who did not have IPA (Table S1). Cross- reaction with either 
the GM0.5 or the LFD assay was observed in 6 of the 38 samples. 
There was a positive LFD test, but a negative GM0.5 test and a nega-
tive LFD test, but a positive GM0.5 test noted in two samples that 
yielded Penicillium spp. Two BAL samples that yielded colonising 
Aspergillus species, A. ochraceous and A. versicolor that were not asso-
ciated with IPA, were both positive by LFD, but only one was positive 
by GM0.5.
A sample with Mucorales gave a positive GM0.5 test, but a neg-
ative LFD test. The BAL sample that yielded Blastomyces dermatiditis 
gave a negative LFD test, but a positive GM0.5 test. Both assays were 
negative in two samples that yielded Fusarium spp.
4  | DISCUSSION
We evaluated the diagnostic performance of the prototype Aspergillus 
LFD and GM assays on BAL samples from patients who had high pre-
test probability for IPA. We found that the performance of the pro-
totype LFD assay for the diagnosis of IPA was comparable, but not 
superior, to that of the GM assay.
The prototype LFD assay has been studied in different popula-
tions at risk, including patients with haematological malignancies, 
solid organ transplant recipients, critically ill patients in the ICU and 
patients with chronic pulmonary disease.12-14,16,18-20 These studies 
varied with regard to the populations studied and the diagnostic 
criteria used to define IPA. Some included GM in BAL fluid as a 
diagnostic criterion, and others excluded patients who had possi-
ble IPA. The effect of anti- mould prophylaxis on test performance 
was generally not taken into account. The conclusion from these 
TABLE  2 LFD and GM results in patients with proven/probable invasive pulmonary aspergillosis
Patient risk factor IPA categorya
Anti- mould 
prophylaxis at 
time of BAL CT chest findings
BAL culture 
result LFD result GM result (ODI)
Heart transplant 
recipient)
Probable No Ground glass opacities, dense 
pulmonary nodules with halo sign
A. fumigatus Negative Positive (6.14)b
Lung transplant 
recipient
Probable No Ground glass opacities, pulmonary 
nodules
A. fumigatus Negative Negative (0.14)
Auto- immune 
disease on steroids
Probable No Cavitary lesion, air crescent sign A. fumigatus Negative Positive (1.36)
Lung transplant 
recipient
Probable VORI Dense pulmonary nodules with 
halo sign, ground glass opacities
A. fumigatus Negative Positive (4.38)
Auto- immune 
disease on steroids
Probable No Ground glass opacities, pulmonary 
nodules
A. nidulans Positive (++) Positive (6.95)
Renal transplant 
recipient
Proven No Dense pulmonary nodules with 
halo sign, cavitary lesion, ground 
glass opacities
A. fumigatus Positive (++) Positive (7.87)
Critical illness Probable No Ground glass opacities, pulmonary 
nodules
A. fumigatus Negative Negative (0.24)b
Lung transplant 
recipient
Probable POSA Ground glass opacities, pulmonary 
nodules
Aspergillus 
spp.
Positive (++) Positive (0.61)
BAL, bronchoalveolar lavage; GM, galactomannan; IPA, invasive pulmonary aspergillosis; LFD, lateral flow device; ODI, optic density index; POSA, posa-
conazole; VORI, voriconazole.
aPatients met the definition of probable IPA by EORTC/MSG criteria6 and also met the definition of putative IPA by the criteria proposed by Blot et al15.
bBAL GM testing performed retrospectively.
8  |     CASTILLO eT AL.
studies was that prototype LFD had high specificity and NPV, but 
only modest sensitivity and PPV. However, a recent review noted 
sensitivity as high as 73% when results from the various studies 
were combined.21
Biomarkers for the diagnosis of IPA appeared to perform better in 
prior studies when used in patients who have haematological malig-
nancies or have received a HCT.7,8 However, the variability of these 
tests has been noted in other patient populations at risk for IPA. A 
recent meta- analysis found that the performance of GM in BAL fluid 
showed large variability in performance depending on the population 
studied and the cut- off value used.22 For this reason, we evaluated 
the performance of both tests in different population groups stratified 
according to their risk for IPA.
Specificity of the prototype LFD and GM0.5 assays was similar in 
the various subgroups that were studied, including solid organ trans-
plant recipients. These findings differ from prior studies using BAL 
fluid that showed that the prototype LFD assay provided improved 
specificity when compared with the GM assay.14,16 This could be in 
part due to the large number of lung transplant recipients and the large 
number of false positive GM tests in BAL fluid reported in both of 
those prior studies.
Prior reports have shown that increasing the cut- off value for the 
GM assay to an ODI ≥1.0 improved specificity and only slightly de-
creased sensitivity.13,22 We found little difference comparing the two 
cut- off points, and the higher cut- off had no impact on the perfor-
mance of GM overall or in specific patient groups.
TABLE  3 Performance of LFD and GM in BAL samples from patients at high risk of invasive pulmonary aspergillosis (IPA): single assay vs 
combination of assays (union and intersection analyses)
Analysis Test Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI)
Proven/probable vs non- IPA
Individual assay LFD 38 (9, 76) 94 (87, 98) 38 (9, 76) 94 (87, 98)
GM0.5 75 (35, 97) 89 (80, 94) 38 (15, 65) 98 (91, 100)
GM1.0 62 (24, 91) 92 (84, 97) 42 (15, 72) 96 (90, 99)
Union GM0.5 or LFD 75 (35, 97) 86 (77, 93) 33 (13, 59) 97 (91, 100)
GM1.0 or LFD 75 (35, 97) 90 (81, 95) 40 (16, 68) 98 (91, 100)
Intersection GM0.5 and LFD 38 (9, 76) 97 (90, 99) 50 (12, 88) 94 (88, 98)
GM1.0 and LFD 25 (3, 65) 97 (90, 99) 40 (5, 85) 93 (86, 98)
Proven/probable/possible vs non- IPA
Individual assay LFD 19 (7, 39) 94 (87, 98) 50 (19, 81) 80 (71, 87)
GM0.5 27 (12, 48) 89 (80, 94) 41 (18, 67) 80 (71, 88)
GM1.0 23 (9, 44) 92 (84, 97) 46 (19, 75) 80 (71, 87)
Union GM0.5 or LFD 35 (17, 56) 86 (77, 93) 43 (22, 66) 82 (72, 89)
GM1.0 or LFD 35 (17, 56) 90 (81, 95) 50 (26, 74) 82 (73, 89)
Intersection GM0.5 and LFD 12 (2, 30) 97 (90, 99) 50 (12, 88) 79 (70, 86)
GM1.0 and LFD 8 (1, 25) 97 (90, 99) 40 (5, 85) 78 (69, 85)
BAL, bronchoalveolar lavage; GM0.5, galactomannan cut- off ≥0.5; GM1.0, galactomannan cut- off ≥1.0; LFD, lateral flow device; NPV, negative predictive 
value; PPV, positive predictive value. Union analysis implies that either GM or LFD should be positive for the diagnosis of invasive pulmonary aspergillosis. 
Intersection analysis implies that both GM and LFD should be positive for the diagnosis of invasive pulmonary aspergillosis.
Risk group
Number of 
BAL tested (%)
Sensitivity Specificity
LFD GM0.5 P value LFD GM0.5 P value
Classical risk factors 
for IPA
78 14 22 .32 98 93 .08
Non- classical risk 
factors for IPA
36 50 50 NA 88 81 .32
Haematological 
diseases
33 7 7 NA 100 100 NA
Solid organ 
transplant
27 33 67 .32 95 90 .32
Non- haematological/
non- transplant
54 33 33 NA 92 83 .16
NA, not applicable.
TABLE  4 Test performance in BAL for 
the diagnosis of proven/probable invasive 
pulmonary aspergillosis (IPA) in different 
subgroups of patients based on their risk
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We noted that the prototype LFD assay showed only a non- 
significant trend towards higher specificity when compared with that 
of GM0.5 and GM1.0. There are two potential explanations for this 
finding. First, most of the patients in the group with haematological 
malignancies or HCT had possible IPA and were receiving anti- mould 
prophylaxis at the time the BAL was performed; this likely led to nega-
tive fungal cultures and negative results with the GM and LFD assays. 
Second, most patients in our study with proven/probable IPA did not 
have a haematological malignancy or HCT, and were from popula-
tions in which both GM and LFD assays have demonstrated variable 
performance.8
Data on the effect of anti- mould drugs on the performance of bio-
marker testing for the diagnosis of IPA are conflicting.19,20,23-26 Eigl 
et al19 reported on the effect of prophylaxis among 60 patients with 
proven/probable IPA, noting a significant decrease in the sensitivity 
of prototype LFD and GM assays performed on BAL fluid of patients 
taking anti- mould prophylaxis. Similar findings have been noted on the 
performance of the GM assay on serum.25,26 In our study, the use of 
anti- mould agents at the time of bronchoscopy did not affect speci-
ficity of either test, but did, however, significantly decrease the NPV 
of both assays. This observation denotes an important limitation for 
both tests.
Molecular techniques, such as real- time PCR, have become in-
creasingly useful in the diagnosis of IPA and are likely to be included 
as microbiological criteria in the upcoming revision of the EORTC/
MSG Guidelines.27,28 Several authors have reported on the use of a 
combination of biomarkers, including PCR, to enhance the diagnosis 
of IPA.13,20,29-31 Johnson et al20 found good agreement between the 
prototype LFD and PCR on BAL fluid from 32 patients, a third of whom 
had probable/proven IPA. Hoenigl et al13 using BAL specimens from 
high- risk patients showed that combining GM1.0 with prototype LFD 
or PCR resulted in an increase in sensitivity to 94% and 100% respec-
tively. We found that using a combination of both prototype LFD and 
GM0.5 led to only a slight increase in sensitivity over the individual 
assays. The intersection analysis in which both assays had to yield a 
positive result predictably increased the specificity, but only slightly, 
and led to very low sensitivity.
False positive LFD results and cross- reactivity with other fungal 
antigens have been previously noted. Based on early in vitro studies, 
the mAb JF5 used in the prototype LFD could cross- react with an-
tigens from Paecilomyces variotii and Penicillium spp.10 False positive 
LFD results have been reported previously with Penicillium spp. and 
occurred with one BAL sample in our study.12,14 Additionally, colonis-
ing non- pathogenic Aspergillus spp. not thought to be causing disease, 
give positive results with the LFD assay.12,14
A major limitation to our study is the small number of patients who 
had proven/probable IPA. Unfortunately, this limitation is commonly 
encountered in studies dealing with IPA and other invasive fungal infec-
tions. The incidence of proven/probable IPA in our cohort was similar 
to that previously reported in other multicentre studies.3,32 However, 
because we excluded biomarkers as microbiological criterion for the 
diagnosis of IPA, it is conceivable that some patients with probable 
IPA may have been classified as possible IPA. Another limitation is that 
we included a small number of patients for whom several samples, col-
lected >2 weeks apart, were studied, perhaps weakening the analysis. 
Our study was conducted in a single centre, and thus, our findings and 
conclusions may not be applicable to other centres.
Although the incidence of IPA appears to be decreasing with the 
implementation of preventative measures, such as antifungal prophy-
laxis in high- risk patients, IPA remains a fatal disease if not promptly 
diagnosed and treated. For this reason, it is important to develop new 
tools for the diagnosis of IPA and to evaluate their application in the 
real world of clinical medicine. When the prototype LFD test was de-
veloped, it was perceived as a useful addition to the diagnostic arma-
mentarium of IPA, and early studies were promising. It is inexpensive, 
simple to perform and results are available in minutes. These features 
made it a very attractive point of care test to help clinicians screen 
for IPA so that prompt intervention could ensue. However, our results 
confirm the findings of other studies, which indicated that the sensi-
tivity of the LFD in BAL fluid may be lower than desired. With current 
advances in molecular technology, it is likely that a more sensitive 
test may be developed that utilises the highly specific Aspergillus JF5 
monoclonal antibody that forms the basis for the current LFD assay.
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